Simplify US Equity PLUS Managed Futures Strategy ETF (CTAP) Stock Price

26.70 ▼ -1.36 (-4.85%)
Open: 28.06 Vol: 426.01K Day's range: 26.67 - 28.06 Jul 27, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
CTAP Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 26.80▼ 26.86▼ 26.86▼ 27.94▼ 26.96▼
MA10 27.09▼ 27.44▼ 27.44▼ 27.68▼ 27.62▼
MA20 27.67▼ 27.99▼ 27.94▼ 27.09▼ 28.38▼
MA50 28.10▼ 27.83▼ 27.66▼ 28.61▼ N/A    
MA100 27.76▼ 27.30▼ 27.01▼ 28.60▼ N/A    
MA200 27.08▼ 27.22▼ 28.19▼ N/A     N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.113▼ -0.208▼ -0.215▼ 0.168▲ N/A    
RSI 15.745▼ 22.627▼ 27.284▼ 40.599▼ 46.570▼
STOCH 0.000▼ 2.381▼ 2.165▼ 64.883     18.879▼
WILL %R -100.000▼ -100.000▼ -100.000▼ -83.588▼ -85.363▼
CCI -72.257     -106.027▼ -106.017▼ -37.929     -64.725    
Latest Filters Detected On CTAP
RSI $CTAP RSI(14) Crossed Below 50 Set Alert
▼ MACD $CTAP MACD(12,26,9) Crossed Below Zero Set Alert
MA $CTAP Price Crossed Below MA(26) Set Alert
MA $CTAP Price Crossed Below MA(13) Set Alert
MA $CTAP Price Crossed Below MA(7) Set Alert
CDL $CTAP Marubozu Candlestick Pattern Detected Set Alert
Simplify US Equity PLUS Managed Futures Strategy ETF News
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment ...
Monday, May 18, 2020 01:05 AM
SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and ...
BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical ...
Tuesday, April 21, 2020 03:15 AM
Westport, CT, April 21, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that on April 16, 2020 its subsidiary ViralClear Pharmaceuticals, ...
cTAP to Present Late-breaking Results Supporting Advancements in Clinical Trial Design for Duchenne Muscular Dystrophy at the World Muscle Society Congress
Monday, October 01, 2018 01:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, pre-competitive global coalition in Duchenne muscular dystrophy, today announced the ...
CTAP historical stock data
date open high low close volume
27/07/26 28.06 28.06 26.67 26.70 426,008
24/07/26 27.56 28.19 27.56 28.06 14,796
23/07/26 28.89 28.89 28.48 28.48 18,663
22/07/26 28.62 28.62 28.3101 28.36 866,155
21/07/26 28.02 28.17 27.95 28.12 3,195,005
20/07/26 27.48 27.72 27.48 27.57 12,253
17/07/26 27.09 27.5617 27.09 27.338 47,517
16/07/26 27.46 28.20 27.1001 27.17 22,442
15/07/26 27.54 27.59 27.16 27.5353 24,420
14/07/26 27.61 27.66 27.3601 27.50 34,956
Quote Details
52wk Low:24.949
52wk High:33.64
Vol:426.01K
Avg Vol(3m):2.5M
1Y Chng:+0.00%
1M Chng:-7.03%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00